Tag: DBV Technologies
DBV Technologies Reports Positive Three-Year, Long Term Data from Phase III...
Patients demonstrated durable, long-term clinical benefit with an additional two years of treatment.
DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut...
If approved, Viaskin Peanut would be the first and only epicutaneous immunotherapy indicated for this potentially life-threatening condition in children.
FAQ for Palforzia, About to Become the First FDA Approved Therapy...
What it is, what it treats, who it is for, how it is used, et al.
DBV Technologies Submits Biologics License Application to FDA for Viaskin Peanut...
This submission addresses the additional data needed on manufacturing procedures and quality controls which were communicated by the FDA in December.
Fare Responds to Final ICER Review of Breakthrough Peanut Allergy Therapies
FARE expresses its deep concerns with the final evidence report on two breakthrough peanut allergy therapies issued Wednesday by ICER.
Asthma and Allergy Foundation of America Responds to Premature ICER Review...
The AAFA addresses concerns
regarding the Final Evidence Report released by the ICER.
ICER’s Final Report on Peanut Allergy Treatments: Clinical Evidence Does Not...
The report evaluates Viaskin® Peanut and AR101, as well as non-commercialized oral immunotherapy (OIT).
Asthma and Allergy Foundation of America Elevates Patient Voice in ICER...
Affirms Burden of Food Allergies on Families, Patients, and Caregivers.
Joint Statement on Peanut Allergy Therapy Review
Organizations representing patients and allergists urge ICER to adopt a more patient-driven approach to assessing immunotherapies for peanut allergy.
DBV to Resubmit Application to FDA for Viaskin Peanut Approval in...
Company allays concerns that BLA would not be resubmitted.
